Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Switzerland
/
Pharmaceuticals & Biotech
Create a narrative
Roche Holding Community
SWX:ROG Community
3
Narratives
written by author
0
Comments
on narratives written by author
219
Fair Values set
on narratives written by author
Community Investing Ideas
Roche Holding
Popular
Undervalued
Overvalued
Roche Holding
BA
bazza
Community Contributor
Roche Holding will see a 4.2576% revenue growth shaking the market
Valuation ### **Analyse der Roche Jahreszahlen 2024: Wachstum setzt sich fort, Herausforderungen bleiben_20250130 #### Zusammenfassung der Ergebnisse Roche hat für das Jahr 2024 ein solides Wachstum von 7 % auf 60,5 Mrd. CHF erzielt, was die Erwartungen leicht übertroffen hat.
View narrative
CHF 302.06
FV
15.2% undervalued
intrinsic discount
5.07%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
13
users have followed this narrative
7 months ago
author updated this narrative
Roche Holding
AN
AnalystLowTarget
Consensus Narrative from 19 Analysts
Regulatory Scrutiny And Generic Competition Will Erode Pricing Power
Key Takeaways Intensifying global pricing reforms, increasing biosimilar competition, and mounting regulatory demands will significantly pressure Roche's revenue, margins, and long-term profitability. Rising R&D costs, disruptive new technologies, and shifting payer priorities threaten Roche's innovation pipeline and ability to sustain premium pricing for novel therapies.
View narrative
CHF 230.00
FV
11.3% overvalued
intrinsic discount
-0.20%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
2 days ago
author updated this narrative
Roche Holding
AN
AnalystConsensusTarget
Consensus Narrative from 19 Analysts
Diagnostics, Pipeline And Automation Will Fuel Future Success
Key Takeaways Expanding innovative diagnostics and advancing high-value biologics pipelines position Roche for strong global growth and resilient revenues across diverse markets. Strategic investments in automation, AI, and emerging markets drive margin expansion, lower costs, and reduce reliance on older, patent-sensitive products.
View narrative
CHF 298.13
FV
14.1% undervalued
intrinsic discount
2.27%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
129
users have followed this narrative
4 days ago
author updated this narrative
Your Valuation for
ROG
ROG
Roche Holding
Your Fair Value
CHF
Current Price
CHF 256.00
5.0% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
73b
2015
2018
2021
2024
2025
2027
2030
Revenue CHF 73.3b
Earnings CHF 10.9b
Advanced
Set Fair Value